Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To assess patient reported treatment satisfaction and medication tolerability in
virologically suppressed HIV-1 infected adults who are at least 65 years of age who switch to
a bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination regimen.